Table 2.
Overview of current clinical trials in the field of HNSCC targeting NRs. The NCI protocol ID is given in bold (for further details see: http://www.cancer.gov/CLINICALTRIALS).
| NR | Clinical trial / identifier | Drug | Tumor entity | Phase |
|---|---|---|---|---|
| PPAR | Pioglitazone in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia/NCT00099021 | Pioglitazone | Head and Neck Cancer Precancerous/Nonmalignant Condition | Phase II ongoing |
| Rosiglitazone in Preventing Oral Cancer in Patients With Oral Leukoplakia/NCT00369174 | Rosiglitazone | Head and Neck Cancer Precancerous/Nonmalignant Condition | Phase II completed | |
|
| ||||
| RAR | Chemoprevention Study of Oral Cavity Squamous Cell Carcinoma/NCT00201279 | 13-cis Retinoic acid | Oral Cavity Squamous Cell Carcinoma | Phase III completed |
| Isotretinoin Plus Interferon in Treating Patients With Recurrent Cancer/NCT00002506 | Isotretinoin (combined with Interferon a) | Head and Neck Cancer Esophageal Cancer | Phase II ongoing | |
| Isotretinoin, Interferon Alpha, and Vitamin E in Treating Patients With Stage III or Stage IV Head and Neck Cancer/NCT00054561 | Isotretinoin (combined with Interferon a and Vitamin E) | Head and Neck Cancer | Phase III completed | |
|
| ||||
| ER | Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors/NCT00002608 | Tamoxifen (combined with Cisplatin and Doxorubicin) | Head and Neck Cancer | Phase II completed |